0.3984
Schlusskurs vom Vortag:
$0.4003
Offen:
$0.3932
24-Stunden-Volumen:
81,880
Relative Volume:
0.35
Marktkapitalisierung:
$29.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-68.80M
KGV:
-0.3405
EPS:
-1.17
Netto-Cashflow:
$-59.06M
1W Leistung:
+11.12%
1M Leistung:
-10.45%
6M Leistung:
-31.11%
1J Leistung:
-55.85%
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Vergleichen Sie PASG mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PASG
Passage Bio Inc
|
0.4014 | 29.80M | 0 | -68.80M | -59.06M | -1.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
451.83 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
538.44 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
319.48 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
559.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-29 | Fortgesetzt | Wedbush | Outperform |
2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
2021-07-01 | Eingeleitet | Raymond James | Outperform |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
2021-02-04 | Eingeleitet | Guggenheim | Buy |
2021-01-25 | Eingeleitet | Wedbush | Outperform |
2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-12-11 | Eingeleitet | Citigroup | Neutral |
2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
2020-03-24 | Eingeleitet | Cowen | Outperform |
2020-03-24 | Eingeleitet | Goldman | Buy |
2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Passage Bio, Inc. (NASDAQ:PASG) Stake Cut by Two Sigma Investments LP - Defense World
Two Sigma Investments LP Makes New Investment in BioVie Inc. (NASDAQ:BIVI) - Defense World
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
American Battery Technology (NASDAQ:ABAT) Shares Purchased by Two Sigma Investments LP - Defense World
Millennium Management LLC Purchases Shares of 37,704 Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Squarepoint Ops LLC Has $36,000 Stake in Passage Bio, Inc. (NASDAQ:PASG) - Defense World
Semrush Holdings, Inc. (NASDAQ:SEMR) Shares Purchased by Bank of America Corp DE - Defense World
Lumina Gold (OTCMKTS:LMGDF) Trading Down 0.3% – Here’s Why - Defense World
Obsidian Energy (OTCMKTS:OBELF) Shares Up 2.7% – Here’s Why - Defense World
Carbios SAS (OTCMKTS:COOSF) Stock Price Up 5% – Here’s Why - Defense World
Suncrest Bank (OTCMKTS:SBKK) Shares Up 1% – Should You Buy? - Defense World
Color Star Technology (NASDAQ:CSCW) Trading 0.5% Higher – Here’s What Happened - Defense World
Inventiva (NASDAQ:IVA) Stock Price Up 0.8% – Here’s Why - Defense World
Fury Gold Mines (NYSEAMERICAN:FURY) Stock Price Down 3.2% – Here’s Why - Defense World
Nano Magic (OTCMKTS:NMGX) Shares Up 5% – What’s Next? - Defense World
Jane Street Group LLC Grows Holdings in Passage Bio, Inc. (NASDAQ:PASG) - Defense World
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Passage Bio, Inc. (NASDAQ:PASG) Shares Purchased by Northern Trust Corp - Defense World
Two Sigma Investments LP Has $1.93 Million Stake in Haleon plc (NYSE:HLN) - Defense World
Passage Bio Adopts Key Proposals at Annual Meeting - TipRanks
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Position in Talkspace, Inc. (NASDAQ:TALK) - Defense World
D. E. Shaw & Co. Inc. Increases Holdings in 908 Devices Inc. (NASDAQ:MASS) - Defense World
VintaBio Showcases Breakthrough Gene Therapy Manufacturing Platform - MyChesCo
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG St - GuruFocus
Cubist Systematic Strategies LLC Grows Holdings in Intevac, Inc. (NASDAQ:IVAC) - Defense World
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MyChesCo
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MSN
Wedbush Issues Pessimistic Estimate for Passage Bio Earnings - Defense World
Gm1 Gangliosidosis Treatment Market in 2025 Detailed Study - openPR.com
Dimensional Fund Advisors LP Has $1.14 Million Stock Holdings in Traeger, Inc. (NYSE:COOK) - Defense World
TransAct Technologies Incorporated (NASDAQ:TACT) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World
Tower Research Capital LLC TRC Acquires 7,927 Shares of The E.W. Scripps Company (NASDAQ:SSP) - Defense World
Braskem Marks 15 Years of I’m green Bio-Based Portfolio with Expanded Production - MyChesCo
Passage Bio Reports Q1 2025 Financial Results - TipRanks
Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com
Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com
Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus
Passage BIO, Inc. SEC 10-Q Report - TradingView
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - The Manila Times
Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World
2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked - BioSpace
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MyChesCo
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Passage Bio Inc-Aktie (PASG) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC | 10% Owner |
Jun 26 '25 |
Sale |
0.33 |
213,257 |
70,375 |
6,066,343 |
ORBIMED ADVISORS LLC | 10% Owner |
Jun 25 '25 |
Sale |
0.33 |
138,800 |
45,804 |
6,279,600 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):